<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT04455932</url>
  </required_header>
  <id_info>
    <org_study_id>2019/PID15472</org_study_id>
    <nct_id>NCT04455932</nct_id>
  </id_info>
  <brief_title>HCC Surveillance: Comparison of Abbreviated Non-contrast MRI and Ultrasound Surveillance in Cirrhotic Patients With Suboptimal Ultrasound Visualisation</brief_title>
  <official_title>HCC Surveillance: Comparison of Abbreviated Non-contrast MRI and Ultrasound Surveillance in Cirrhotic Patients With Suboptimal Ultrasound Visualisation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Concord Repatriation General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Concord Repatriation General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      All international guidelines recommend 6-monthly ultrasound surveillance for patients at risk&#xD;
      for liver cancer (hepatocellular carcinoma or HCC), such as patients with cirrhosis. The aim&#xD;
      of surveillance is to detect HCC at an early stage when it is still potentially curable.&#xD;
      Currently only 4 out of 10 HCCs are detected at the early stage.&#xD;
&#xD;
      Ultrasound surveillance for HCC has a wide ranging sensitivity, dependent on many factors&#xD;
      such as operator experience, patient body habitus and liver parenchymal heterogeneity due to&#xD;
      chronic liver disease and cirrhosis. In a select group of patients, surveillance ultrasound&#xD;
      can be suboptimal or near non-diagnostic.&#xD;
&#xD;
      Currently no guideline offers an alternative surveillance tool for patients who have&#xD;
      suboptimal surveillance ultrasounds.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators plan to conduct a prospective study to examine the diagnostic performance&#xD;
      of abbreviated non-contrast MRI (aNC-MRI) versus ultrasound, in a select group of cirrhotic&#xD;
      patients with poor ultrasound visualisation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">March 2027</completion_date>
  <primary_completion_date type="Anticipated">December 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HCC detection with US surveillance versus aNC-MRI surveillance</measure>
    <time_frame>3 or 5 years</time_frame>
    <description>The detection of hepatic malignancy on the two modalities will be compared&#xD;
Sensitivity, specificity, PPV and NPV of HCC detection with US surveillance vs aNC-MRI surveillance&#xD;
Correlation with diagnostic imaging (multiphase CT or MRI) and/or histopathology as a reference standard&#xD;
For the diagnosis of HCC we will accept&#xD;
Imaging diagnosis based on the Liver Imaging Reporting and Data System (LI-RADS)&#xD;
Any pathological proof on biopsy or excision The HCC will then be staged based on the Barcelona clinic liver cancer (BCLC) staging system&#xD;
For the diagnosis of non-HCC hepatic malignancy we will accept&#xD;
Imaging diagnosis based on the Liver Imaging Reporting and Data System (LI-RADS)&#xD;
Any pathological proof on biopsy or excision</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">476</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>HCC</condition>
  <arm_group>
    <arm_group_label>HCC surveillance with US and aNC-MRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Abbreviated non-contrast MRI of the liver</intervention_name>
    <description>every 6 months</description>
    <arm_group_label>HCC surveillance with US and aNC-MRI</arm_group_label>
    <other_name>aNC-MRI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Ultrasound surveillance</intervention_name>
    <description>every 6 months</description>
    <arm_group_label>HCC surveillance with US and aNC-MRI</arm_group_label>
    <other_name>US surveillance</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Multiphase contrast-enhanced liver MRI</intervention_name>
    <description>screening</description>
    <arm_group_label>HCC surveillance with US and aNC-MRI</arm_group_label>
    <other_name>Multiphase liver MRI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          -  Patients with cirrhosis (all causes of cirrhosis, except obscure causes such as&#xD;
             vascular or congenital fibrosis) AND reduced visualisation of their liver on&#xD;
             ultrasound (vB and vC).&#xD;
&#xD;
          -  The criteria of cirrhosis can be obtained with any of the following methods:&#xD;
&#xD;
               1. Histologically by liver biopsy&#xD;
&#xD;
               2. Past signs of decompensated liver disease such as ascites, encephalopathy,&#xD;
                  varices or bacterial peritonitis&#xD;
&#xD;
               3. Clinically suspicion of cirrhosis PLUS one of the following:&#xD;
&#xD;
                    1. Radiological evidence of morphologic changes of the liver and evidence of&#xD;
                       portal hypertension on US, CT or MRI examinations, including the&#xD;
                       identification of hepatic surface nodularity, splenomegaly, portal&#xD;
                       collaterals, varices and ascites&#xD;
&#xD;
                    2. Fibroscan (transient elastography) median liver stiffness &gt;12.5 kPa, the&#xD;
                       Fibroscan must be performed by an experienced technician and interpreted by&#xD;
                       the hepatologist&#xD;
&#xD;
                    3. Platelet count &lt;100 (x10^9/L) with no alternative cause&#xD;
&#xD;
          -  Absence of previous history or current suspicion of HCC - Absence of HCC is defined by&#xD;
             liver US, multiphase CT or contrast-enhanced MRI within 6 months prior to surveillance&#xD;
&#xD;
          -  Patient is able to comply with scheduled visits, evaluation plans and other study&#xD;
             procedures in the opinion of the investigator&#xD;
&#xD;
          -  Patient is willing to provide written informed consent&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Contraindications to MRI scan (defibrillator, pacemaker, metallic foreign body, severe&#xD;
             claustrophobia etc.)&#xD;
&#xD;
          -  Contraindications to gadolinium&#xD;
&#xD;
          -  Age above 85 years old or younger than 20 years old&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  Any other condition which, in the opinion of the Investigator, would make the patient&#xD;
             unsuitable for enrolment for the trial or could interfere with the completion of the&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jessica Yang, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Concord Repatriation General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jessica Yang, MBBS</last_name>
    <phone>+61297676495</phone>
    <email>jessica.yang1@health.nsw.gov.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Isaac Lui, MD</last_name>
    <email>dr.isaac.lui@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yu Xuan Kitzing</last_name>
    </contact>
    <investigator>
      <last_name>Yu Xuan Kitzing</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Simone Strasser</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Concord Repatriation General Hospital</name>
      <address>
        <city>Concord</city>
        <state>New South Wales</state>
        <zip>2139</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Yang</last_name>
    </contact>
    <investigator>
      <last_name>Alice Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emily He</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeff Chang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jessica Yang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gosford Hospital</name>
      <address>
        <city>Gosford</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jonathan Ho</last_name>
    </contact>
    <contact_backup>
      <last_name>Susanna Won</last_name>
    </contact_backup>
    <investigator>
      <last_name>Jonathan Ho</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Susanna Won</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Satbir Singh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dean Rabinowitz</last_name>
    </contact>
    <investigator>
      <last_name>Dean Rabinowitz</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephen Riordan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jacob George</last_name>
    </contact>
    <investigator>
      <last_name>Anthony Peduto</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jacob George</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kate McLean</last_name>
    </contact>
    <investigator>
      <last_name>Kate McLean</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katherine Stuart</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caroline Tallis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital Melbourne</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tom Sutherland</last_name>
    </contact>
    <investigator>
      <last_name>Tom Sutherland</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Austin Hospital</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Numan Kutaiba</last_name>
    </contact>
    <investigator>
      <last_name>Numan Kutaiba</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Perth Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>James Seow</last_name>
    </contact>
    <investigator>
      <last_name>James Seow</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wendy Cheng</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Shore Hospital</name>
      <address>
        <city>Takapuna</city>
        <state>Auckland</state>
        <zip>0620</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chris McKee</last_name>
    </contact>
    <investigator>
      <last_name>Chris McKee</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jash Agraval</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Perry</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
  </location_countries>
  <link>
    <url>https://www.acr.org/-/media/ACR/Files/RADS/LI-RADS/CEUS-LI-RADS-2017-Core.pdf?la=en%20n.d</url>
    <description>US LIRADS CORE 2017</description>
  </link>
  <results_reference>
    <citation>Son JH, Choi SH, Kim SY, Jang HY, Byun JH, Won HJ, Lee SJ, Lim YS. Validation of US Liver Imaging Reporting and Data System Version 2017 in Patients at High Risk for Hepatocellular Carcinoma. Radiology. 2019 Aug;292(2):390-397. doi: 10.1148/radiol.2019190035. Epub 2019 Jun 18.</citation>
    <PMID>31210614</PMID>
  </results_reference>
  <results_reference>
    <citation>Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med. 2014 Apr 1;11(4):e1001624. doi: 10.1371/journal.pmed.1001624. eCollection 2014 Apr.</citation>
    <PMID>24691105</PMID>
  </results_reference>
  <results_reference>
    <citation>Tzartzeva K, Obi J, Rich NE, Parikh ND, Marrero JA, Yopp A, Waljee AK, Singal AG. Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis. Gastroenterology. 2018 May;154(6):1706-1718.e1. doi: 10.1053/j.gastro.2018.01.064. Epub 2018 Feb 6.</citation>
    <PMID>29425931</PMID>
  </results_reference>
  <results_reference>
    <citation>Hanna RF, Miloushev VZ, Tang A, Finklestone LA, Brejt SZ, Sandhu RS, Santillan CS, Wolfson T, Gamst A, Sirlin CB. Comparative 13-year meta-analysis of the sensitivity and positive predictive value of ultrasound, CT, and MRI for detecting hepatocellular carcinoma. Abdom Radiol (NY). 2016 Jan;41(1):71-90. doi: 10.1007/s00261-015-0592-8.</citation>
    <PMID>26830614</PMID>
  </results_reference>
  <results_reference>
    <citation>Colli A, Fraquelli M, Casazza G, Massironi S, Colucci A, Conte D, Duca P. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol. 2006 Mar;101(3):513-23. doi: 10.1111/j.1572-0241.2006.00467.x.</citation>
    <PMID>16542288</PMID>
  </results_reference>
  <results_reference>
    <citation>Chernyak V, Fowler KJ, Kamaya A, Kielar AZ, Elsayes KM, Bashir MR, Kono Y, Do RK, Mitchell DG, Singal AG, Tang A, Sirlin CB. Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients. Radiology. 2018 Dec;289(3):816-830. doi: 10.1148/radiol.2018181494. Epub 2018 Sep 25.</citation>
    <PMID>30251931</PMID>
  </results_reference>
  <results_reference>
    <citation>European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018 Jul;69(1):182-236. doi: 10.1016/j.jhep.2018.03.019. Epub 2018 Apr 5. No abstract available. Erratum In: J Hepatol. 2019 Apr;70(4):817.</citation>
    <PMID>29628281</PMID>
  </results_reference>
  <results_reference>
    <citation>D'Avola D, Labgaa I, Villanueva A. Natural history of nonalcoholic steatohepatitis/nonalcoholic fatty liver disease-hepatocellular carcinoma: Magnitude of the problem from a hepatology clinic perspective. Clin Liver Dis (Hoboken). 2016 Oct 27;8(4):100-104. doi: 10.1002/cld.579. eCollection 2016 Oct. No abstract available.</citation>
    <PMID>31041073</PMID>
  </results_reference>
  <results_reference>
    <citation>Saunders D, Seidel D, Allison M, Lyratzopoulos G. Systematic review: the association between obesity and hepatocellular carcinoma - epidemiological evidence. Aliment Pharmacol Ther. 2010 May;31(10):1051-63. doi: 10.1111/j.1365-2036.2010.04271.x. Epub 2010 Feb 18.</citation>
    <PMID>20175765</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang C, Wang X, Gong G, Ben Q, Qiu W, Chen Y, Li G, Wang L. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. Int J Cancer. 2012 Apr 1;130(7):1639-48. doi: 10.1002/ijc.26165. Epub 2011 Jul 28.</citation>
    <PMID>21544812</PMID>
  </results_reference>
  <results_reference>
    <citation>Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016 Jul;64(1):73-84. doi: 10.1002/hep.28431. Epub 2016 Feb 22.</citation>
    <PMID>26707365</PMID>
  </results_reference>
  <results_reference>
    <citation>Chitturi S, Wong VW, Chan WK, Wong GL, Wong SK, Sollano J, Ni YH, Liu CJ, Lin YC, Lesmana LA, Kim SU, Hashimoto E, Hamaguchi M, Goh KL, Fan J, Duseja A, Dan YY, Chawla Y, Farrell G, Chan HL. The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2: Management and special groups. J Gastroenterol Hepatol. 2018 Jan;33(1):86-98. doi: 10.1111/jgh.13856. No abstract available.</citation>
    <PMID>28692197</PMID>
  </results_reference>
  <results_reference>
    <citation>Benson AB 3rd, D'Angelica MI, Abbott DE, Abrams TA, Alberts SR, Saenz DA, Are C, Brown DB, Chang DT, Covey AM, Hawkins W, Iyer R, Jacob R, Karachristos A, Kelley RK, Kim R, Palta M, Park JO, Sahai V, Schefter T, Schmidt C, Sicklick JK, Singh G, Sohal D, Stein S, Tian GG, Vauthey JN, Venook AP, Zhu AX, Hoffmann KG, Darlow S. NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017. J Natl Compr Canc Netw. 2017 May;15(5):563-573. doi: 10.6004/jnccn.2017.0059.</citation>
    <PMID>28476736</PMID>
  </results_reference>
  <results_reference>
    <citation>Burak KW, Sherman M. Hepatocellular carcinoma: Consensus, controversies and future directions. A report from the Canadian Association for the Study of the Liver Hepatocellular Carcinoma Meeting. Can J Gastroenterol Hepatol. 2015 May;29(4):178-84. doi: 10.1155/2015/824263.</citation>
    <PMID>25965437</PMID>
  </results_reference>
  <results_reference>
    <citation>Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, Zhu AX, Murad MH, Marrero JA. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018 Jan;67(1):358-380. doi: 10.1002/hep.29086. No abstract available.</citation>
    <PMID>28130846</PMID>
  </results_reference>
  <results_reference>
    <citation>Kokudo N, Hasegawa K, Akahane M, Igaki H, Izumi N, Ichida T, Uemoto S, Kaneko S, Kawasaki S, Ku Y, Kudo M, Kubo S, Takayama T, Tateishi R, Fukuda T, Matsui O, Matsuyama Y, Murakami T, Arii S, Okazaki M, Makuuchi M. Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines). Hepatol Res. 2015 Jan;45(2). doi: 10.1111/hepr.12464.</citation>
    <PMID>25625806</PMID>
  </results_reference>
  <results_reference>
    <citation>Marrero JA, Ahn J, Rajender Reddy K; Americal College of Gastroenterology. ACG clinical guideline: the diagnosis and management of focal liver lesions. Am J Gastroenterol. 2014 Sep;109(9):1328-47; quiz 1348. doi: 10.1038/ajg.2014.213. Epub 2014 Aug 19.</citation>
    <PMID>25135008</PMID>
  </results_reference>
  <results_reference>
    <citation>Korean Liver Cancer Study Group (KLCSG); National Cancer Center, Korea (NCC). 2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma. Gut Liver. 2015 May 23;9(3):267-317. doi: 10.5009/gnl14460.</citation>
    <PMID>25918260</PMID>
  </results_reference>
  <results_reference>
    <citation>Besa C, Lewis S, Pandharipande PV, Chhatwal J, Kamath A, Cooper N, Knight-Greenfield A, Babb JS, Boffetta P, Padron N, Sirlin CB, Taouli B. Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion-weighted and T1-weighted imaging at the delayed phase post gadoxetic acid. Abdom Radiol (NY). 2017 Jan;42(1):179-190. doi: 10.1007/s00261-016-0841-5. Erratum In: Abdom Radiol (NY). 2017 Jul 28;:</citation>
    <PMID>27448609</PMID>
  </results_reference>
  <results_reference>
    <citation>Tillman BG, Gorman JD, Hru JM, Lee MH, King MC, Sirlin CB, Marks RM. Diagnostic per-lesion performance of a simulated gadoxetate disodium-enhanced abbreviated MRI protocol for hepatocellular carcinoma screening. Clin Radiol. 2018 May;73(5):485-493. doi: 10.1016/j.crad.2017.11.013. Epub 2017 Dec 12.</citation>
    <PMID>29246586</PMID>
  </results_reference>
  <results_reference>
    <citation>Lee JY, Huo EJ, Weinstein S, Santos C, Monto A, Corvera CU, Yee J, Hope TA. Evaluation of an abbreviated screening MRI protocol for patients at risk for hepatocellular carcinoma. Abdom Radiol (NY). 2018 Jul;43(7):1627-1633. doi: 10.1007/s00261-017-1339-5.</citation>
    <PMID>29018942</PMID>
  </results_reference>
  <results_reference>
    <citation>Chan MV, McDonald SJ, Ong YY, Mastrocostas K, Ho E, Huo YR, Santhakumar C, Lee AU, Yang J. HCC screening: assessment of an abbreviated non-contrast MRI protocol. Eur Radiol Exp. 2019 Dec 18;3(1):49. doi: 10.1186/s41747-019-0126-1.</citation>
    <PMID>31853685</PMID>
  </results_reference>
  <results_reference>
    <citation>Park SH, Kim B, Kim SY, Shim YS, Kim JH, Huh J, Kim HJ, Kim KW, Lee SS. Abbreviated MRI with optional multiphasic CT as an alternative to full-sequence MRI: LI-RADS validation in a HCC-screening cohort. Eur Radiol. 2020 Apr;30(4):2302-2311. doi: 10.1007/s00330-019-06546-5. Epub 2019 Dec 19.</citation>
    <PMID>31858203</PMID>
  </results_reference>
  <results_reference>
    <citation>Lewis S, Kamath A, Chatterji M, Patel A, Shyknevsky I, Dyvorne HA, Kuehn B, Taouli B. Diffusion-weighted imaging of the liver in patients with chronic liver disease: comparison of monopolar and bipolar diffusion gradients for image quality and lesion detection. AJR Am J Roentgenol. 2015 Jan;204(1):59-68. doi: 10.2214/AJR.13.11695.</citation>
    <PMID>25539238</PMID>
  </results_reference>
  <results_reference>
    <citation>Whang S, Choi MH, Choi JI, Youn SY, Kim DH, Rha SE. Comparison of diagnostic performance of non-contrast MRI and abbreviated MRI using gadoxetic acid in initially diagnosed hepatocellular carcinoma patients: a simulation study of surveillance for hepatocellular carcinomas. Eur Radiol. 2020 Aug;30(8):4150-4163. doi: 10.1007/s00330-020-06754-4. Epub 2020 Mar 12.</citation>
    <PMID>32166493</PMID>
  </results_reference>
  <results_reference>
    <citation>Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, Roberts LR, Heimbach JK. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018 Aug;68(2):723-750. doi: 10.1002/hep.29913. No abstract available.</citation>
    <PMID>29624699</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 27, 2020</study_first_submitted>
  <study_first_submitted_qc>July 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2020</study_first_posted>
  <last_update_submitted>September 6, 2021</last_update_submitted>
  <last_update_submitted_qc>September 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Concord Repatriation General Hospital</investigator_affiliation>
    <investigator_full_name>Dr Jessica Yang</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Ultrasound</keyword>
  <keyword>MRI</keyword>
  <keyword>HCC</keyword>
  <keyword>Hepatocellular carcinoma</keyword>
  <keyword>aMRI</keyword>
  <keyword>NC-aMRI</keyword>
  <keyword>Screening</keyword>
  <keyword>Surveillance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Extracts</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT04455932
org study id: 2019/PID15472
nct id: NCT04455932
lead sponsor: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
All international guidelines recommend 6-monthly ultrasound surveillance for patients at risk
      for liver cancer (hepatocellular carcinoma or HCC), such as patients with cirrhosis. The aim
      of surveillance is to detect HCC at an early stage when it is still potentially curable.
      Currently only 4 out of 10 HCCs are detected at the early stage.

      Ultrasound surveillance for HCC has a wide ranging sensitivity, dependent on many factors
      such as operator experience, patient body habitus and liver parenchymal heterogeneity due to
      chronic liver disease and cirrhosis. In a select group of patients, surveillance ultrasound
      can be suboptimal or near non-diagnostic.

      Currently no guideline offers an alternative surveillance tool for patients who have
      suboptimal surveillance ultrasounds.
The investigators plan to conduct a prospective study to examine the diagnostic performance
      of abbreviated non-contrast MRI (aNC-MRI) versus ultrasound, in a select group of cirrhotic
      patients with poor ultrasound visualisation.
allocation: N/A
intervention model: Single Group Assignment
primary purpose: Screening
masking: None (Open Label)
measure: HCC detection with US surveillance versus aNC-MRI surveillance
time frame: 3 or 5 years
description: The detection of hepatic malignancy on the two modalities will be compared
Sensitivity, specificity, PPV and NPV of HCC detection with US surveillance vs aNC-MRI surveillance
Correlation with diagnostic imaging (multiphase CT or MRI) and/or histopathology as a reference standard
For the diagnosis of HCC we will accept
Imaging diagnosis based on the Liver Imaging Reporting and Data System (LI-RADS)
Any pathological proof on biopsy or excision The HCC will then be staged based on the Barcelona clinic liver cancer (BCLC) staging system
For the diagnosis of non-HCC hepatic malignancy we will accept
Imaging diagnosis based on the Liver Imaging Reporting and Data System (LI-RADS)
Any pathological proof on biopsy or excision
arm group label: HCC surveillance with US and aNC-MRI
arm group type: Experimental
intervention type: Diagnostic Test
intervention name: Abbreviated non-contrast MRI of the liver
description: every 6 months
arm group label: HCC surveillance with US and aNC-MRI
other name: aNC-MRI
intervention type: Diagnostic Test
intervention name: Ultrasound surveillance
description: every 6 months
arm group label: HCC surveillance with US and aNC-MRI
other name: US surveillance
intervention type: Diagnostic Test
intervention name: Multiphase contrast-enhanced liver MRI
description: screening
arm group label: HCC surveillance with US and aNC-MRI
other name: Multiphase liver MRI
criteria: 
gender: All
minimum age: 20 Years
maximum age: 85 Years
healthy volunteers: No
last name: Jessica Yang, MBBS
role: Principal Investigator
affiliation: Concord Repatriation General Hospital
last name: Jessica Yang, MBBS
phone: +61297676495
email: jessica.yang1@health.nsw.gov.au
last name: Isaac Lui, MD
email: dr.isaac.lui@gmail.com
facility: 
status: Not yet recruiting
contact: 
investigator: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
investigator: 
investigator: 
investigator: 
facility: 
status: Not yet recruiting
contact: 
contact backup: 
investigator: 
investigator: 
investigator: 
facility: 
status: Not yet recruiting
contact: 
investigator: 
investigator: 
facility: 
status: Not yet recruiting
contact: 
investigator: 
investigator: 
facility: 
status: Not yet recruiting
contact: 
investigator: 
investigator: 
investigator: 
facility: 
status: Not yet recruiting
contact: 
investigator: 
facility: 
status: Not yet recruiting
contact: 
investigator: 
facility: 
status: Not yet recruiting
contact: 
investigator: 
investigator: 
facility: 
status: Not yet recruiting
contact: 
investigator: 
investigator: 
investigator: 
country: Australia
country: New Zealand
url: https://www.acr.org/-/media/ACR/Files/RADS/LI-RADS/CEUS-LI-RADS-2017-Core.pdf?la=en%20n.d
description: US LIRADS CORE 2017
citation: Son JH, Choi SH, Kim SY, Jang HY, Byun JH, Won HJ, Lee SJ, Lim YS. Validation of US Liver Imaging Reporting and Data System Version 2017 in Patients at High Risk for Hepatocellular Carcinoma. Radiology. 2019 Aug;292(2):390-397. doi: 10.1148/radiol.2019190035. Epub 2019 Jun 18.
PMID: 31210614
citation: Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med. 2014 Apr 1;11(4):e1001624. doi: 10.1371/journal.pmed.1001624. eCollection 2014 Apr.
PMID: 24691105
citation: Tzartzeva K, Obi J, Rich NE, Parikh ND, Marrero JA, Yopp A, Waljee AK, Singal AG. Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis. Gastroenterology. 2018 May;154(6):1706-1718.e1. doi: 10.1053/j.gastro.2018.01.064. Epub 2018 Feb 6.
PMID: 29425931
citation: Hanna RF, Miloushev VZ, Tang A, Finklestone LA, Brejt SZ, Sandhu RS, Santillan CS, Wolfson T, Gamst A, Sirlin CB. Comparative 13-year meta-analysis of the sensitivity and positive predictive value of ultrasound, CT, and MRI for detecting hepatocellular carcinoma. Abdom Radiol (NY). 2016 Jan;41(1):71-90. doi: 10.1007/s00261-015-0592-8.
PMID: 26830614
citation: Colli A, Fraquelli M, Casazza G, Massironi S, Colucci A, Conte D, Duca P. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol. 2006 Mar;101(3):513-23. doi: 10.1111/j.1572-0241.2006.00467.x.
PMID: 16542288
citation: Chernyak V, Fowler KJ, Kamaya A, Kielar AZ, Elsayes KM, Bashir MR, Kono Y, Do RK, Mitchell DG, Singal AG, Tang A, Sirlin CB. Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients. Radiology. 2018 Dec;289(3):816-830. doi: 10.1148/radiol.2018181494. Epub 2018 Sep 25.
PMID: 30251931
citation: European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018 Jul;69(1):182-236. doi: 10.1016/j.jhep.2018.03.019. Epub 2018 Apr 5. No abstract available. Erratum In: J Hepatol. 2019 Apr;70(4):817.
PMID: 29628281
citation: D'Avola D, Labgaa I, Villanueva A. Natural history of nonalcoholic steatohepatitis/nonalcoholic fatty liver disease-hepatocellular carcinoma: Magnitude of the problem from a hepatology clinic perspective. Clin Liver Dis (Hoboken). 2016 Oct 27;8(4):100-104. doi: 10.1002/cld.579. eCollection 2016 Oct. No abstract available.
PMID: 31041073
citation: Saunders D, Seidel D, Allison M, Lyratzopoulos G. Systematic review: the association between obesity and hepatocellular carcinoma - epidemiological evidence. Aliment Pharmacol Ther. 2010 May;31(10):1051-63. doi: 10.1111/j.1365-2036.2010.04271.x. Epub 2010 Feb 18.
PMID: 20175765
citation: Wang C, Wang X, Gong G, Ben Q, Qiu W, Chen Y, Li G, Wang L. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. Int J Cancer. 2012 Apr 1;130(7):1639-48. doi: 10.1002/ijc.26165. Epub 2011 Jul 28.
PMID: 21544812
citation: Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016 Jul;64(1):73-84. doi: 10.1002/hep.28431. Epub 2016 Feb 22.
PMID: 26707365
citation: Chitturi S, Wong VW, Chan WK, Wong GL, Wong SK, Sollano J, Ni YH, Liu CJ, Lin YC, Lesmana LA, Kim SU, Hashimoto E, Hamaguchi M, Goh KL, Fan J, Duseja A, Dan YY, Chawla Y, Farrell G, Chan HL. The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2: Management and special groups. J Gastroenterol Hepatol. 2018 Jan;33(1):86-98. doi: 10.1111/jgh.13856. No abstract available.
PMID: 28692197
citation: Benson AB 3rd, D'Angelica MI, Abbott DE, Abrams TA, Alberts SR, Saenz DA, Are C, Brown DB, Chang DT, Covey AM, Hawkins W, Iyer R, Jacob R, Karachristos A, Kelley RK, Kim R, Palta M, Park JO, Sahai V, Schefter T, Schmidt C, Sicklick JK, Singh G, Sohal D, Stein S, Tian GG, Vauthey JN, Venook AP, Zhu AX, Hoffmann KG, Darlow S. NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017. J Natl Compr Canc Netw. 2017 May;15(5):563-573. doi: 10.6004/jnccn.2017.0059.
PMID: 28476736
citation: Burak KW, Sherman M. Hepatocellular carcinoma: Consensus, controversies and future directions. A report from the Canadian Association for the Study of the Liver Hepatocellular Carcinoma Meeting. Can J Gastroenterol Hepatol. 2015 May;29(4):178-84. doi: 10.1155/2015/824263.
PMID: 25965437
citation: Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, Zhu AX, Murad MH, Marrero JA. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018 Jan;67(1):358-380. doi: 10.1002/hep.29086. No abstract available.
PMID: 28130846
citation: Kokudo N, Hasegawa K, Akahane M, Igaki H, Izumi N, Ichida T, Uemoto S, Kaneko S, Kawasaki S, Ku Y, Kudo M, Kubo S, Takayama T, Tateishi R, Fukuda T, Matsui O, Matsuyama Y, Murakami T, Arii S, Okazaki M, Makuuchi M. Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines). Hepatol Res. 2015 Jan;45(2). doi: 10.1111/hepr.12464.
PMID: 25625806
citation: Marrero JA, Ahn J, Rajender Reddy K; Americal College of Gastroenterology. ACG clinical guideline: the diagnosis and management of focal liver lesions. Am J Gastroenterol. 2014 Sep;109(9):1328-47; quiz 1348. doi: 10.1038/ajg.2014.213. Epub 2014 Aug 19.
PMID: 25135008
citation: Korean Liver Cancer Study Group (KLCSG); National Cancer Center, Korea (NCC). 2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma. Gut Liver. 2015 May 23;9(3):267-317. doi: 10.5009/gnl14460.
PMID: 25918260
citation: Besa C, Lewis S, Pandharipande PV, Chhatwal J, Kamath A, Cooper N, Knight-Greenfield A, Babb JS, Boffetta P, Padron N, Sirlin CB, Taouli B. Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion-weighted and T1-weighted imaging at the delayed phase post gadoxetic acid. Abdom Radiol (NY). 2017 Jan;42(1):179-190. doi: 10.1007/s00261-016-0841-5. Erratum In: Abdom Radiol (NY). 2017 Jul 28;:
PMID: 27448609
citation: Tillman BG, Gorman JD, Hru JM, Lee MH, King MC, Sirlin CB, Marks RM. Diagnostic per-lesion performance of a simulated gadoxetate disodium-enhanced abbreviated MRI protocol for hepatocellular carcinoma screening. Clin Radiol. 2018 May;73(5):485-493. doi: 10.1016/j.crad.2017.11.013. Epub 2017 Dec 12.
PMID: 29246586
citation: Lee JY, Huo EJ, Weinstein S, Santos C, Monto A, Corvera CU, Yee J, Hope TA. Evaluation of an abbreviated screening MRI protocol for patients at risk for hepatocellular carcinoma. Abdom Radiol (NY). 2018 Jul;43(7):1627-1633. doi: 10.1007/s00261-017-1339-5.
PMID: 29018942
citation: Chan MV, McDonald SJ, Ong YY, Mastrocostas K, Ho E, Huo YR, Santhakumar C, Lee AU, Yang J. HCC screening: assessment of an abbreviated non-contrast MRI protocol. Eur Radiol Exp. 2019 Dec 18;3(1):49. doi: 10.1186/s41747-019-0126-1.
PMID: 31853685
citation: Park SH, Kim B, Kim SY, Shim YS, Kim JH, Huh J, Kim HJ, Kim KW, Lee SS. Abbreviated MRI with optional multiphasic CT as an alternative to full-sequence MRI: LI-RADS validation in a HCC-screening cohort. Eur Radiol. 2020 Apr;30(4):2302-2311. doi: 10.1007/s00330-019-06546-5. Epub 2019 Dec 19.
PMID: 31858203
citation: Lewis S, Kamath A, Chatterji M, Patel A, Shyknevsky I, Dyvorne HA, Kuehn B, Taouli B. Diffusion-weighted imaging of the liver in patients with chronic liver disease: comparison of monopolar and bipolar diffusion gradients for image quality and lesion detection. AJR Am J Roentgenol. 2015 Jan;204(1):59-68. doi: 10.2214/AJR.13.11695.
PMID: 25539238
citation: Whang S, Choi MH, Choi JI, Youn SY, Kim DH, Rha SE. Comparison of diagnostic performance of non-contrast MRI and abbreviated MRI using gadoxetic acid in initially diagnosed hepatocellular carcinoma patients: a simulation study of surveillance for hepatocellular carcinomas. Eur Radiol. 2020 Aug;30(8):4150-4163. doi: 10.1007/s00330-020-06754-4. Epub 2020 Mar 12.
PMID: 32166493
citation: Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, Roberts LR, Heimbach JK. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018 Aug;68(2):723-750. doi: 10.1002/hep.29913. No abstract available.
PMID: 29624699
responsible party type: Principal Investigator
investigator affiliation: Concord Repatriation General Hospital
investigator full name: Dr Jessica Yang
investigator title: Principal Investigator
mesh term: Carcinoma, Hepatocellular
mesh term: Liver Extracts
sharing ipd: No